Ofloxacin Ophthalmic Solution Recalled Nationwide for Manufacturing Quality Issues
Akorn, Inc. is recalling Ofloxacin Ophthalmic Solution 0.3% due to manufacturing quality deviations. The recall affects 65,006 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall due to manufacturing quality deviations with no reported illnesses or injuries documented in the source. Class II recalls indicate potential for adverse effects but lack reported incidents, fitting the Moderate category for voluntary precautionary recalls.
Plain-English summary
Akorn, Inc. is recalling Ofloxacin Ophthalmic Solution, USP 0.3% in 5 mL bottles (NDC: 13985-602-05) due to deviations from Current Good Manufacturing Practice (CGMP) standards. The recall affects 65,006 bottles that were distributed nationwide in the United States.
This is a Class II voluntary recall initiated by the manufacturer on October 13, 2022, after the firm identified manufacturing deviations in its production processes. The FDA formally classified the recall on January 13, 2023.
Patients currently using this medication should contact their healthcare provider or pharmacist regarding the recall. Do not stop using the medication without medical advice, as this is a prescription product requiring professional guidance. The affected lot numbers are 11B26A (expiration date 1/31/2023) and 1H02A (expiration date 7/31/2023).
Healthcare providers and patients can check the FDA's drug recall database for additional information and updates on this recall.
The recalled product
- Product
- Ofloxacin Ophthalmic Solution, USP 0.3%, 5 mL per bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045; Distributed by: MWI, Boise, ID 83705. NDC: 13985-602-05
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- Affected units
- 65,006
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 11B26A
- EXP 1/31/2023
- 1H02A
- EXP 7/31/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09